Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

Rapid research autopsy is a stealthy but growing contributor to cancer research.

Duregon E, Schneider J, DeMarzo AM, Hooper JE.

Cancer. 2019 Sep 1;125(17):2915-2919. doi: 10.1002/cncr.32184. Epub 2019 May 15. No abstract available.

PMID:
31090935
2.

AXL Is a Putative Tumor Suppressor and Dormancy Regulator in Prostate Cancer.

Axelrod HD, Valkenburg KC, Amend SR, Hicks JL, Parsana P, Torga G, DeMarzo AM, Pienta KJ.

Mol Cancer Res. 2019 Feb;17(2):356-369. doi: 10.1158/1541-7786.MCR-18-0718. Epub 2018 Oct 5.

PMID:
30291220
3.

Mutational profiles of breast cancer metastases from a rapid autopsy series reveal multiple evolutionary trajectories.

Avigdor BE, Cimino-Mathews A, DeMarzo AM, Hicks JL, Shin J, Sukumar S, Fetting J, Argani P, Park BH, Wheelan SJ.

JCI Insight. 2017 Dec 21;2(24). pii: 96896. doi: 10.1172/jci.insight.96896.

4.

Pharmacodynamic and pharmacokinetic neoadjuvant study of hedgehog pathway inhibitor Sonidegib (LDE-225) in men with high-risk localized prostate cancer undergoing prostatectomy.

Ross AE, Hughes RM, Glavaris S, Ghabili K, He P, Anders NM, Harb R, Tosoian JJ, Marchionni L, Schaeffer EM, Partin AW, Allaf ME, Bivalacqua TJ, Chapman C, O'Neal T, DeMarzo AM, Hurley PJ, Rudek MA, Antonarakis ES.

Oncotarget. 2017 Oct 26;8(61):104182-104192. doi: 10.18632/oncotarget.22115. eCollection 2017 Nov 28.

5.

MYC Targeted Long Noncoding RNA DANCR Promotes Cancer in Part by Reducing p21 Levels.

Lu Y, Hu Z, Mangala LS, Stine ZE, Hu X, Jiang D, Xiang Y, Zhang Y, Pradeep S, Rodriguez-Aguayo C, Lopez-Berestein G, DeMarzo AM, Sood AK, Zhang L, Dang CV.

Cancer Res. 2018 Jan 1;78(1):64-74. doi: 10.1158/0008-5472.CAN-17-0815. Epub 2017 Nov 27.

6.

c-Myc Antagonises the Transcriptional Activity of the Androgen Receptor in Prostate Cancer Affecting Key Gene Networks.

Barfeld SJ, Urbanucci A, Itkonen HM, Fazli L, Hicks JL, Thiede B, Rennie PS, Yegnasubramanian S, DeMarzo AM, Mills IG.

EBioMedicine. 2017 Apr;18:83-93. doi: 10.1016/j.ebiom.2017.04.006. Epub 2017 Apr 5.

7.

Concurrent nuclear ERG and MYC protein overexpression defines a subset of locally advanced prostate cancer: Potential opportunities for synergistic targeted therapeutics.

Udager AM, DeMarzo AM, Shi Y, Hicks JL, Cao X, Siddiqui J, Jiang H, Chinnaiyan AM, Mehra R.

Prostate. 2016 Jun;76(9):845-53. doi: 10.1002/pros.23175. Epub 2016 Mar 8.

8.

Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance.

Martin AM, Nirschl TR, Nirschl CJ, Francica BJ, Kochel CM, van Bokhoven A, Meeker AK, Lucia MS, Anders RA, DeMarzo AM, Drake CG.

Prostate Cancer Prostatic Dis. 2015 Dec;18(4):325-32. doi: 10.1038/pcan.2015.39. Epub 2015 Aug 11.

9.

Characterization of 1577 primary prostate cancers reveals novel biological and clinicopathologic insights into molecular subtypes.

Tomlins SA, Alshalalfa M, Davicioni E, Erho N, Yousefi K, Zhao S, Haddad Z, Den RB, Dicker AP, Trock BJ, DeMarzo AM, Ross AE, Schaeffer EM, Klein EA, Magi-Galluzzi C, Karnes RJ, Jenkins RB, Feng FY.

Eur Urol. 2015 Oct;68(4):555-67. doi: 10.1016/j.eururo.2015.04.033. Epub 2015 May 8.

10.

Heterogeneity of PTEN and ERG expression in prostate cancer on core needle biopsies: implications for cancer risk stratification and biomarker sampling.

Shah RB, Bentley J, Jeffery Z, DeMarzo AM.

Hum Pathol. 2015 May;46(5):698-706. doi: 10.1016/j.humpath.2015.01.008. Epub 2015 Jan 29.

PMID:
25724568
11.

USP22 regulates oncogenic signaling pathways to drive lethal cancer progression.

Schrecengost RS, Dean JL, Goodwin JF, Schiewer MJ, Urban MW, Stanek TJ, Sussman RT, Hicks JL, Birbe RC, Draganova-Tacheva RA, Visakorpi T, DeMarzo AM, McMahon SB, Knudsen KE.

Cancer Res. 2014 Jan 1;74(1):272-86. doi: 10.1158/0008-5472.CAN-13-1954. Epub 2013 Nov 6.

12.

Small renal mass biopsy--how, what and when: report from an international consensus panel.

Tsivian M, Rampersaud EN Jr, del Pilar Laguna Pes M, Joniau S, Leveillee RJ, Shingleton WB, Aron M, Kim CY, DeMarzo AM, Desai MM, Meler JD, Donovan JF, Klingler HC, Sopko DR, Madden JF, Marberger M, Ferrandino MN, Polascik TJ.

BJU Int. 2014 Jun;113(6):854-63. doi: 10.1111/bju.12470. Epub 2014 Jan 17. Review.

13.

The diet as a cause of human prostate cancer.

Nelson WG, Demarzo AM, Yegnasubramanian S.

Cancer Treat Res. 2014;159:51-68. doi: 10.1007/978-3-642-38007-5_4. Review.

14.

Engineering a prostate-specific membrane antigen-activated tumor endothelial cell prodrug for cancer therapy.

Denmeade SR, Mhaka AM, Rosen DM, Brennen WN, Dalrymple S, Dach I, Olesen C, Gurel B, Demarzo AM, Wilding G, Carducci MA, Dionne CA, Møller JV, Nissen P, Christensen SB, Isaacs JT.

Sci Transl Med. 2012 Jun 27;4(140):140ra86. doi: 10.1126/scitranslmed.3003886. Erratum in: Sci Transl Med. 2012 Jul 18;4(143):143er4.

15.

Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors.

Yachida S, Vakiani E, White CM, Zhong Y, Saunders T, Morgan R, de Wilde RF, Maitra A, Hicks J, Demarzo AM, Shi C, Sharma R, Laheru D, Edil BH, Wolfgang CL, Schulick RD, Hruban RH, Tang LH, Klimstra DS, Iacobuzio-Donahue CA.

Am J Surg Pathol. 2012 Feb;36(2):173-84. doi: 10.1097/PAS.0b013e3182417d36.

16.

Expression status and prognostic significance of mammalian target of rapamycin pathway members in urothelial carcinoma of urinary bladder after cystectomy.

Schultz L, Albadine R, Hicks J, Jadallah S, DeMarzo AM, Chen YB, Nielsen ME, Gonzalgo ML, Sidransky D, Schoenberg M, Netto GJ.

Cancer. 2010 Dec 1;116(23):5517-26. doi: 10.1002/cncr.25502. Epub 2010 Oct 11. Erratum in: Cancer. 2011 Nov 1;117(21):5021. Neilsen, Matthew E [corrected to Nielsen, Matthew E].

17.

Cell-autonomous intracellular androgen receptor signaling drives the growth of human prostate cancer initiating cells.

Vander Griend DJ, D'Antonio J, Gurel B, Antony L, Demarzo AM, Isaacs JT.

Prostate. 2010 Jan 1;70(1):90-9. doi: 10.1002/pros.21043.

18.

TMPRSS2-ERG gene fusion status in minute (minimal) prostatic adenocarcinoma.

Albadine R, Latour M, Toubaji A, Haffner M, Isaacs WB, A Platz E, Meeker AK, Demarzo AM, Epstein JI, Netto GJ.

Mod Pathol. 2009 Nov;22(11):1415-22. doi: 10.1038/modpathol.2009.121. Epub 2009 Sep 4.

19.

Cyclophosphamide augments antitumor immunity: studies in an autochthonous prostate cancer model.

Wada S, Yoshimura K, Hipkiss EL, Harris TJ, Yen HR, Goldberg MV, Grosso JF, Getnet D, Demarzo AM, Netto GJ, Anders R, Pardoll DM, Drake CG.

Cancer Res. 2009 May 15;69(10):4309-18. doi: 10.1158/0008-5472.CAN-08-4102. Epub 2009 May 12.

20.

Individual and cumulative effect of prostate cancer risk-associated variants on clinicopathologic variables in 5,895 prostate cancer patients.

Kader AK, Sun J, Isaacs SD, Wiley KE, Yan G, Kim ST, Fedor H, DeMarzo AM, Epstein JI, Walsh PC, Partin AW, Trock B, Zheng SL, Xu J, Isaacs W.

Prostate. 2009 Aug 1;69(11):1195-205. doi: 10.1002/pros.20970.

21.

TMPRSS2-ERG gene fusions are infrequent in prostatic ductal adenocarcinomas.

Lotan TL, Toubaji A, Albadine R, Latour M, Herawi M, Meeker AK, DeMarzo AM, Platz EA, Epstein JI, Netto GJ.

Mod Pathol. 2009 Mar;22(3):359-65. doi: 10.1038/modpathol.2008.236. Epub 2009 Jan 16.

22.

The role of CD133 in normal human prostate stem cells and malignant cancer-initiating cells.

Vander Griend DJ, Karthaus WL, Dalrymple S, Meeker A, DeMarzo AM, Isaacs JT.

Cancer Res. 2008 Dec 1;68(23):9703-11. doi: 10.1158/0008-5472.CAN-08-3084.

23.

Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing.

Sfanos KS, Bruno TC, Maris CH, Xu L, Thoburn CJ, DeMarzo AM, Meeker AK, Isaacs WB, Drake CG.

Clin Cancer Res. 2008 Jun 1;14(11):3254-61. doi: 10.1158/1078-0432.CCR-07-5164.

24.

Effect of DNA methylation on identification of aggressive prostate cancer.

Alumkal JJ, Zhang Z, Humphreys EB, Bennett C, Mangold LA, Carducci MA, Partin AW, Garrett-Mayer E, DeMarzo AM, Herman JG.

Urology. 2008 Dec;72(6):1234-9. doi: 10.1016/j.urology.2007.12.060. Epub 2008 Apr 2.

25.

The N-Myc down regulated Gene1 (NDRG1) Is a Rab4a effector involved in vesicular recycling of E-cadherin.

Kachhap SK, Faith D, Qian DZ, Shabbeer S, Galloway NL, Pili R, Denmeade SR, DeMarzo AM, Carducci MA.

PLoS One. 2007 Sep 5;2(9):e844.

26.

Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma.

Chuang AY, DeMarzo AM, Veltri RW, Sharma RB, Bieberich CJ, Epstein JI.

Am J Surg Pathol. 2007 Aug;31(8):1246-55.

PMID:
17667550
27.

Early prostate cancer antigen expression in predicting presence of prostate cancer in men with histologically negative biopsies.

Hansel DE, DeMarzo AM, Platz EA, Jadallah S, Hicks J, Epstein JI, Partin AW, Netto GJ.

J Urol. 2007 May;177(5):1736-40.

PMID:
17437801
28.

Expanding the histologic spectrum of mucinous tubular and spindle cell carcinoma of the kidney.

Fine SW, Argani P, DeMarzo AM, Delahunt B, Sebo TJ, Reuter VE, Epstein JI.

Am J Surg Pathol. 2006 Dec;30(12):1554-60.

PMID:
17122511
29.

Immunohistochemical staining of precursor forms of prostate-specific antigen (proPSA) in metastatic prostate cancer.

Parwani AV, Marlow C, Demarzo AM, Mikolajczyk SD, Rittenhouse HG, Veltri RW, Chan TY.

Am J Surg Pathol. 2006 Oct;30(10):1231-6.

PMID:
17001152
30.

Epithelial architectural destruction is necessary for bone marrow derived cell contribution to regenerating prostate epithelium.

Palapattu GS, Meeker A, Harris T, Collector MI, Sharkis SJ, DeMarzo AM, Warlick C, Drake CG, Nelson WG.

J Urol. 2006 Aug;176(2):813-8.

PMID:
16813953
31.
32.

In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor.

van der Heijden MS, Brody JR, Dezentje DA, Gallmeier E, Cunningham SC, Swartz MJ, DeMarzo AM, Offerhaus GJ, Isacoff WH, Hruban RH, Kern SE.

Clin Cancer Res. 2005 Oct 15;11(20):7508-15.

33.

Telomere lengths of translocation-associated and nontranslocation-associated sarcomas differ dramatically.

Montgomery E, Argani P, Hicks JL, DeMarzo AM, Meeker AK.

Am J Pathol. 2004 May;164(5):1523-9.

34.

Gene expression profiling identifies clinically relevant subtypes of prostate cancer.

Lapointe J, Li C, Higgins JP, van de Rijn M, Bair E, Montgomery K, Ferrari M, Egevad L, Rayford W, Bergerheim U, Ekman P, DeMarzo AM, Tibshirani R, Botstein D, Brown PO, Brooks JD, Pollack JR.

Proc Natl Acad Sci U S A. 2004 Jan 20;101(3):811-6. Epub 2004 Jan 7.

35.

Pathological and molecular aspects of prostate cancer.

DeMarzo AM, Nelson WG, Isaacs WB, Epstein JI.

Lancet. 2003 Mar 15;361(9361):955-64. Review.

PMID:
12648986
36.

Expression of the DNA-PK binding protein E4-34K fails to confer radiation sensitivity to mammalian cells.

Collis SJ, Ketner GW, Hicks JL, Nelson WG, Demarzo AM, Deweese TL.

Int J Radiat Biol. 2003 Jan;79(1):53-60.

PMID:
12556331
37.

The diet, prostate inflammation, and the development of prostate cancer.

Nelson WG, DeWeese TL, DeMarzo AM.

Cancer Metastasis Rev. 2002;21(1):3-16. Review.

PMID:
12400993
38.

Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk.

Xu J, Zheng SL, Komiya A, Mychaleckyj JC, Isaacs SD, Hu JJ, Sterling D, Lange EM, Hawkins GA, Turner A, Ewing CM, Faith DA, Johnson JR, Suzuki H, Bujnovszky P, Wiley KE, DeMarzo AM, Bova GS, Chang B, Hall MC, McCullough DL, Partin AW, Kassabian VS, Carpten JD, Bailey-Wilson JE, Trent JM, Ohar J, Bleecker ER, Walsh PC, Isaacs WB, Meyers DA.

Nat Genet. 2002 Oct;32(2):321-5. Epub 2002 Sep 16.

PMID:
12244320
39.

A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy.

DeWeese TL, van der Poel H, Li S, Mikhak B, Drew R, Goemann M, Hamper U, DeJong R, Detorie N, Rodriguez R, Haulk T, DeMarzo AM, Piantadosi S, Yu DC, Chen Y, Henderson DR, Carducci MA, Nelson WG, Simons JW.

Cancer Res. 2001 Oct 15;61(20):7464-72.

40.

The molecular pathogenesis of prostate cancer: focus on the earliest steps.

Nelson WG, DeMarzo AM, DeWeese TL.

Eur Urol. 2001 Apr;39 Suppl 4:8-11. No abstract available.

PMID:
11340278
41.

Cancer cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies.

Nelson WG, Simons JW, Mikhak B, Chang JF, DeMarzo AM, Carducci MA, Kim M, Weber CE, Baccala AA, Goeman MA, Clift SM, Ando DG, Levitsky HI, Cohen LK, Sanda MG, Mulligan RC, Partin AW, Carter HB, Piantadosi S, Marshall FF.

Cancer Chemother Pharmacol. 2000;46 Suppl:S67-72.

PMID:
10950151
42.

Genetic alterations in urinary bladder carcinosarcoma: evidence of a common clonal origin.

Halachmi S, DeMarzo AM, Chow NH, Halachmi N, Smith AE, Linn JF, Nativ O, Epstein JI, Schoenberg MP, Sidransky D.

Eur Urol. 2000 Mar;37(3):350-7.

PMID:
10720865
43.

Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer.

Simons JW, Mikhak B, Chang JF, DeMarzo AM, Carducci MA, Lim M, Weber CE, Baccala AA, Goemann MA, Clift SM, Ando DG, Levitsky HI, Cohen LK, Sanda MG, Mulligan RC, Partin AW, Carter HB, Piantadosi S, Marshall FF, Nelson WG.

Cancer Res. 1999 Oct 15;59(20):5160-8.

44.

Effects of the steroid antagonist RU486 on dimerization of the human progesterone receptor.

DeMarzo AM, Oñate SA, Nordeen SK, Edwards DP.

Biochemistry. 1992 Nov 3;31(43):10491-501.

PMID:
1420166
45.

Mechanisms controlling steroid receptor binding to specific DNA sequences.

Edwards DP, DeMarzo AM, Oñate SA, Beck CA, Estes PA, Nordeen SK.

Steroids. 1991 May;56(5):271-8.

PMID:
1652169
46.

Supplemental Content

Loading ...
Support Center